Phase II trial of CDX-3379 and cetuximab in recurrent/metastatic, HPV-negative, cetuximab-resistant head and neck cancer

Authors

Julie E Bauman, University of Arizona
Ricklie Julian, University of Arizona
Nabil F Saba, Emory University
Trisha M Wise-Draper, University of Cincinnati
Douglas R Adkins, Washington University School of Medicine in St. Louis
Paul O'Brien, Medical University of South Carolina
Mary Jo Fidler, Rush University Medical Center
Michael K Gibson, Vanderbilt University Medical Center
Umamaheswar Duvvuri, University of Pittsburgh Medical Center
Margo Heath-Chiozzi, Celldex Therapeutics
Diego Alvarado, Celldex Therapeutics
Richard Gedrich, Celldex Therapeutics
Philip Golden, Celldex Therapeutics
Roger B Cohen, University of Pennsylvania

Journal

Cancers

Publication Date

5-10-2022

Volume

14

Issue

10

First Page

2355

Document Type

Open Access Publication

DOI

10.3390/cancers14102355

Rights and Permissions

Bauman, J.E.; Julian, R.; Saba, N.F.; Wise-Draper, T.M.; Adkins, D.R.; O’Brien, P.; Fidler, M.J.; Gibson, M.K.; Duvvuri, U.; Heath-Chiozzi, M.; Alvarado, D.; Gedrich, R.; Golden, P.; Cohen, R.B. Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer. Cancers 2022, 14, 2355. doi.org/10.3390/cancers14102355 This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Recommended Citation

Bauman, Julie E; Julian, Ricklie; Saba, Nabil F; Wise-Draper, Trisha M; Adkins, Douglas R; O'Brien, Paul; Fidler, Mary Jo; Gibson, Michael K; Duvvuri, Umamaheswar; Heath-Chiozzi, Margo; Alvarado, Diego; Gedrich, Richard; Golden, Philip; and Cohen, Roger B, "Phase II trial of CDX-3379 and cetuximab in recurrent/metastatic, HPV-negative, cetuximab-resistant head and neck cancer." Cancers. 14, 10. 2355 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11987